Major depressive disorder (MDD) symptoms saw significant reductions following a single, short-acting psychedelic intervention in a new Phase IIa randomized controlled trial. MDD is a leading cause of global disability, with many patients unresponsive to conventional antidepressants and psychotherapy. The pursuit of rapid-acting treatments has accelerated, especially for moderate-to-severe cases. Dimethyltryptamine (DMT), a fast-acting psychedelic, is emerging as a potential alternative.
In a double-blind, placebo-controlled study, 34 adults with moderate-to-severe MDD received either a 21.5 mg intravenous dose of DMT or a placebo, infused over 10 minutes, alongside structured psychotherapy. At two weeks, those receiving DMT showed a significantly greater reduction in depression scores compared to the placebo group. Secondary outcomes, including a 50% reduction in symptoms and remission, were also notably improved.
Following the initial blinded phase, all participants were offered an open-label DMT session. Antidepressant effects were sustained for up to three months, with no significant difference observed between those who received one versus two doses. Adverse events were primarily mild-to-moderate, including infusion site pain, nausea, and transient anxiety, with no serious adverse events reported, indicating DMT therapy was well-tolerated in this controlled setting.
Unlike traditional antidepressants that can take weeks to show effects, DMT's rapid pharmacological action offers the potential for faster symptom relief. While this study's sample size was small and follow-up limited, larger trials are necessary to confirm durability, optimal dosing, and safety across broader patient populations. If replicated, these findings suggest short-acting psychedelic interventions like DMT therapy could offer a novel, rapid-acting treatment option for patients with major depressive disorder inadequately treated by existing therapies.